efalizumab


Also found in: Wikipedia.

efalizumab

A recombinant, humanized monoclonal antibody to CD11 a used to treat moderate to severe PSORIASIS.
References in periodicals archive ?
* Autoimmune haemolytic anemia: Occurs 4-6 months after the start of treatment with efalizumab.
Good to excellent responses were achieved with ustekinumab at doses of either 45 mg or 90 mg, depending on body weight, in 9 of 11 psoriasis patients who had experienced treatment failures on multiple biologics, including infliximab (11 patients), etanercept (10), efalizumab (9), adalimumab (7), and golimumab (3) (Int.
Bulloz hastaliklarin ortaya cikisinda psoriasis tedavisinde kullanilan katran, salisilik asit, efalizumab ve adalimumab gibi ajanlar ve fototerapi rol oynayabilir (2-5).
Efalizumab, lokosit fonksiyon-iliskili antijen-1 (LFA-1)'in alt-parcasi olan CD11a'ya karsin gelistirilmis insanlastirilmis monoklonal antikordur.
La literatura muestra ejemplos como el de la talidomida en 1961 y los cerca de 4 000 casos de focomelia asociados a su uso, el aumento de riesgo de muerte de origen cardiovascular y el consumo de antiinfamatorios COX-2 selectivos o de terapia hormonal sustitutiva (17) y recientemente el retiro del mercado de efalizumab por su asociacion con eventos neurologicos adversos (18).
However, risk is a concern because of what happened with the biologic efalizumab (Raptiva), which was taken off the market after three cases (two fatal) of progressive multifocal leukoencephalopathy, a brain infection, were reported in patients treated with the drug for psoriasis.
The Food and Drug Administration has advised prescribers not to initiate Raptiva (efalizumab) treatment for new patients and to engage in discussions with those already on the therapy of avenues for transitioning to alternative treatments.
Off-label uses of biologics in dermatology: rituximab, omalizumab, infliksimab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).
Ng, "The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab," Journal of Pharmaceutical Sciences, vol.
After an effective monoclonal antibody therapy (infliximab, etanercept, and efalizumab), an increase of CD[4.sup.+]CD[25.sup.+]FOXP[3.sup.+] cells in the blood of psoriatic patients is observed as well as in the previously affected skin after treatment with adalimumab (17, 24, 43).
Efalizumab, a monoclonal antibody and a T-cell modulator, has also shown a good response in patients with DLE.